| [1] |
Watson SS, Dane M, Chin K, et al. Microenvironment-mediated mechanisms of resistance to HER2 inhibitors differ between HER2+ breast cancer subtypes[J]. Cell Syst, 2018, 6(3): 329-342.
|
| [2] |
Hynes NE, Macdonald G. ErbB receptors and signaling pathways in cancer[J]. Curr Opin in Cell Biol, 2009, 21(2): 177-184.
|
| [3] |
Uhlmann S, Mannsperger H, Zhang JD, et al. Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer[J]. Mol Syst Biol, 2012, 8: 570-674.
|
| [4] |
He L, Hannon GJ. Micrornas: small RNAs with a big role in gene regulation[J]. Nat Rev Genet, 2004, 5(7): 522-531.
|
| [5] |
Heneghan HM, Miller N, Kelly R, et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease[J]. Oncologist, 2010, 15(7): 673-682.
|
| [6] |
Lowery AJ, Miller N, Devaney A, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer[J]. Breast Cancer Res, 2009, 11(3): R27.
|
| [7] |
Wang B, Zhang QY. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors[J]. J Cancer Res Clin Oncol, 2012, 138(10): 1659-1666.
|
| [8] |
Ma T, Yang L, Zhang J. miRNA-542-3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation[J]. Oncol Rep, 2015, 33(3): 1215-1220.
|
| [9] |
Ahmad A. Current updates on trastuzumab resistance in HER2 overexpressing breast cancers[J]. Adv Exp Med Biol, 2019, 1152: 217-228.
|
| [10] |
Olayioye MA. Update on HER-2 as a target for cancer therapy - intracellular signaling pathways of ErbB2/HER-2 and family members[J]. Breast Cancer Res, 2001, 3(6): 385-389.
|
| [11] |
Browne BC, O'brien N, Duffy MJ, et al. HER-2 signaling and inhibition in breast cancer[J]. Curr Cancer Drug Targets, 2009, 9(3): 419-438.
|
| [12] |
Serra V, Scaltriti M, Prudkin L, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer[J]. Oncogene, 2011, 30(22): 2547-2557.
|
| [13] |
Ponde N, Brandao M, El-Hachem G, et al. Treatment of advanced HER2-positive breast cancer: 2018 and beyond[J]. Cancer Treat Rev, 2018, 67: 10-20.
|
| [14] |
Ferreira GM, Martinez M, Camargo ICC, et al. Melatonin attenuates Her-2, p38 MAPK, p-AKT, and mTOR levels in ovarian carcinoma of ethanol-preferring rats[J]. J Cancer, 2014, 5(9): 728-735.
|
| [15] |
Mori N, Kyo S, Nakamura M, et al. Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer[J]. Br J Cancer, 2010, 103(6): 889-898.
|
| [16] |
Sukawa Y, Yamamoto H, Nosho K, et al. HER2 expression and PI3K-Akt pathway alterations in gastric cancer[J]. Digestion, 2014, 89(1): 12-17.
|
| [17] |
Li N, Bu X, Wu P, et al. The "HER2-PI3K/Akt-FASN Axis" regulated malignant phenotype of colorectal cancer cells[J]. Lipids, 2012, 47(4): 403-411.
|
| [18] |
Asif HM, Sultana S, Ahmed S, et al. HER-2 positive breast cancer - a mini-review[J]. Asian Pac J Cancer Prev, 2016, 17(4): 1609-1615.
|
| [19] |
Hamam R, Hamam D, Alsaleh KA, et al. Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers[J]. Cell Death Dis, 2017, 8(9): e3045.
|
| [20] |
Kian R, Moradi S, Ghorbian S. Role of components of microRNA machinery in carcinogenesis[J]. Exp Oncol, 2018, 40(1): 2-9.
|
| [21] |
Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease[J]. Cell, 2012, 148(6): 1172-1187.
|
| [22] |
Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer[J]. Cancer Res, 2016, 76(13): 3666-3670.
|
| [23] |
Yan TH, Qiu C, Sun J, et al. MiR-877-5p suppresses cell growth, migration and invasion by targeting cyclin dependent kinase 14 and predicts prognosis in hepatocellular carcinoma[J]. Eur Rev Med Pharmaco Sci, 2018, 22(14): 4401-4402.
|
| [24] |
Zhang LQ, Li CL, Cao LJ, et al. microRNA-877 inhibits malignant progression of colorectal cancer by directly targeting MTDH and regulating the PTEN/Akt pathway[J]. Cancer Manag Res, 2019, 11: 2769-2781.
|
| [25] |
Meng FX, Ou J, Liu JY, et al. MicroRNA-877 is downregulated in cervical cancer and directly targets MACC1 to inhibit cell proliferation and invasion[J]. Exp Ther Med, 2019, 18(5): 3650-3658.
|
| [26] |
Li SQ, Zhu Y, Liang Z, et al. Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer[J]. Oncotarget, 2016, 7(32): 51773-51783.
|
| [27] |
Van Schooneveld E, Wildiers H, Vergote I, et al. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management[J]. Breast Cancer Res, 2015, 17: 21-35.
|